FDA NEWS | AZUR 1 Update in Rectal Cancer
Take-home: FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.AZUR-1: 68% cCR12, 76% no evidence of disease ≥1 year, no recurrences in responders (median FU >2 yrs). Nearly ¾ of patients avoided surgery/RT/chemo
About this highlight
- Type
- Regulatory news
- Topic
- Gastrointestinal
